Cibotercept Biosimilar – Anti-ACTR-IIB mAb – Research Grade from ProteoGenix; catalogue PX-TA2154; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Cibotercept Biosimilar, also known as Anti-ACTR-IIB mAb, is a novel therapeutic antibody that has shown great potential in the treatment of various diseases. This biosimilar is a recombinant monoclonal antibody that targets the activin receptor type IIB (ACTR-IIB) protein, making it a promising therapeutic option for a wide range of conditions. In this article, we will explore the structure, activity, and potential applications of Cibotercept Biosimilar in detail.
Cibotercept Biosimilar is a humanized monoclonal antibody that is produced through recombinant DNA technology. It is composed of two heavy chains and two light chains, each of which contains a variable region that specifically binds to the ACTR-IIB protein. The constant region of the antibody is responsible for its effector functions, such as complement activation and antibody-dependent cellular cytotoxicity.
The primary mechanism of action of Cibotercept Biosimilar is the inhibition of the ACTR-IIB protein. ACTR-IIB is a type I receptor for the transforming growth factor-beta (TGF-β) superfamily of proteins, which plays a crucial role in various cellular processes, including cell proliferation, differentiation, and apoptosis. By binding to ACTR-IIB, Cibotercept Biosimilar blocks the downstream signaling pathways of TGF-β, thereby inhibiting its pro-inflammatory and pro-fibrotic effects.
In addition to its inhibitory effects on TGF-β signaling, Cibotercept Biosimilar also has anti-angiogenic properties. It binds to the vascular endothelial growth factor (VEGF) and prevents its interaction with its receptors, thereby inhibiting the formation of new blood vessels. This activity is particularly beneficial in conditions where excessive angiogenesis is involved, such as cancer and rheumatoid arthritis.
Cibotercept Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for various diseases. Some of the potential applications of this antibody include:
1.
Cancer: The overexpression of TGF-β has been linked to tumor growth, invasion, and metastasis in various types of cancer. By inhibiting TGF-β signaling, Cibotercept Biosimilar has the potential to suppress tumor growth and prevent metastasis. Clinical trials are underway to evaluate its efficacy in different types of cancer, including breast, lung, and prostate cancer.
2. Fibrotic diseases: TGF-β is a key mediator of fibrosis, a pathological process characterized by excessive deposition of extracellular matrix proteins. Cibotercept Biosimilar has shown promising results in animal models of fibrotic diseases, such as pulmonary fibrosis and liver fibrosis. Clinical trials are ongoing to assess its potential in the treatment of these conditions.
3. Inflammatory disorders: The dysregulation of TGF-β signaling has been implicated in the pathogenesis of various inflammatory disorders, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. By targeting ACTR-IIB, Cibotercept Biosimilar has the potential to modulate the immune response and alleviate inflammation in these conditions.
Cibotercept Biosimilar is a novel therapeutic antibody that targets the ACTR-IIB protein. By inhibiting TGF-β signaling, it has the potential to treat various diseases, including cancer, fibrotic disorders, and inflammatory conditions. With ongoing clinical trials, this biosimilar holds great promise in the field of therapeutics and may provide a new treatment option for patients with these debilitating conditions.
ProteoGenix catalogue number PX-TA2154. For research use only.
Target: Cibotercept Biosimilar – Anti-ACTR-IIB mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Cibotercept Biosimilar – Anti-ACTR-IIB mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
